title: The analgesic effect of orexin-A in a murine model of chemotherapy-induced neuropathic pain.
abstract: Orexins are neuropeptides that are localized to neurons in the lateral and dorsal hypothalamus but its receptors are distributed to many different regions of the central nervous system. Orexins are implicated in a variety of physiological functions including sleep regulation, energy homeostats, and stress reactions. Furthermore, orexins administered exogenously have been shown to have analgesic effects in animal models. A type of intractable pain in patients is pain due to chemotherapy-induced peripheral neuropathy (CIPN). Several chemotherapeutic agents used for the treatment of malignant diseases induce dose-limiting neuropathic pain that compromises patients' quality of life. Here, we examined the analgesic effect of orexin-A in a murine model of CIPN, and compared it with the effect of duloxetine, the only drug recommended for the treatment of CIPN pain in patients. CIPN was induced in male BALB/c mice by repeated intraperitoneal injection of oxaliplatin, a platinum chemotherapeutic agent used for the treatment of advanced colorectal cancer. Neuropathic mechanical allodynia was assessed by the von Frey test, and the effect on acute thermal pain was assessed by the tail flick test. Intracerebroventricularly administered orexin-A dose-dependently attenuated oxaliplatin-induced mechanical allodynia and increased tail flick latencies. Oxaliplatin-induced mechanical allodynia was completely reversed by orexin-A at a low dose that did not increase tail flick latency. Duloxetine only partially reversed mechanical allodynia and had no effect on tail flick latency. The analgesic effect of orexin-A on oxaliplatin-induced mechanical allodynia was completely antagonized by prior intraperitoneal injection of SB-408124 (orexin type-1 receptor antagonist), but not by prior intraperitoneal injection of TCS-OX2-29 (orexin type-2 receptor antagonist). Our findings suggest that orexin-A is more potent than duloxetine in relieving pain CIPN pain and its analgesic effect is mediated by orexin type-1 receptors. Orexin type-1 receptor agonists may have potential therapeutic roles in the treatment of CIPN pain in patients.
authors.affiliation: Department of Anesthesiology, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba 299-0111, Japan. Electronic address: s-toyama@suite.plala.or.jp.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Toyama
authors.affiliation: Department of Anesthesiology, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba 299-0111, Japan. Electronic address: nshimoya@jikei.ac.jp.
authors.forename: Naohito
authors.initials: N
authors.lastname: Shimoyama
authors.affiliation: Department of Anesthesiology, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba 299-0111, Japan. Electronic address: mshimoy@jikei.ac.jp.
authors.forename: Megumi
authors.initials: M
authors.lastname: Shimoyama
mesh_terms: D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents; D006930:Hyperalgesia / Q000139:chemically induced / Q000188:drug therapy*; D051379:Mice; D009437:Neuralgia / Q000139:chemically induced / Q000188:drug therapy*; D000068797:Orexins / Q000494:pharmacology / Q000627:therapeutic use*; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D010147:Pain Measurement
chemical_list: D000700:Analgesics; D000970:Antineoplastic Agents; D000068797:Orexins; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin
keywords: Neuropathic pain; Orexin; Oxaliplatin